deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT00788463

A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps

Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Conditions Nasal Polyps
Updated 10 times since 2017 Last updated: Aug 25, 2017 Started: Nov 23, 2006 Primary completion: Mar 30, 2009 Completion: Nov 30, 2011
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Nasal Polyps and is currently completed. London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's leads this study, which shows 10 recorded versions since 2006 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Study Description(click to expand)

Aqueous and aerosol delivery of intranasal corticosteroids has never been directly compared previously in patients with nasal polyps and it is unknown whether one is superior. This objective of this study is to compare the efficacy of intranasal beclomethasone by two different delivery systems, aerosol and aqueous spray in patients with nasal polyps. Primary endpoint is the difference in the overall quality of life as measured by the Rhinitis Quality of Life Questionnaire. The secondary endpoint is the change in Nasal Airflow Resistance as measured by rhinomanometry.

Aqueous and aerosol delivery of intranasal corticosteroids has never been directly compared previously in patients with nasal polyps and it is unknown whether one is superior.

This objective of this study is to compare the efficacy of intranasal beclomethasone by two different delivery systems, aerosol and aqueous spray in patients with nasal polyps. Primary endpoint is the difference in the overall quality of life as measured by the Rhinitis Quality of Life Questionnaire. The secondary endpoint is the change in Nasal Airflow Resistance as measured by rhinomanometry.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotUnknown Status~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshotUnknown Status~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshotCompleted~Jan 2025 – ~Apr 2025 · 3 months · monthly snapshotCompleted~Apr 2025 – present · 12 months · monthly snapshotCompleted~Jan 2026 – present · 3 months · monthly snapshotCompleted

Change History

10 versions recorded
  1. Jan 2026 — Present [monthly]

    Completed PHASE2

  2. Apr 2025 — Present [monthly]

    Completed PHASE2

  3. Jan 2025 — Apr 2025 [monthly]

    Completed PHASE2

  4. Sep 2024 — Jan 2025 [monthly]

    Completed PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

Show 5 earlier versions
  1. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  2. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

  3. Sep 2017 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Unknown StatusCompleted

  4. Feb 2017 — Sep 2017 [monthly]

    Unknown Status PHASE2

  5. Jan 2017 — Feb 2017 [monthly]

    Unknown Status PHASE2

    First recorded

Nov 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Data source: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations